Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10937731 | 0.90 | BACE1 (0.47) | ADRA2CTSHRHPGDALDH1A1POLB | |
| SCHEMBL6607753 | 0.84 | SMN1; SMN2 (0.57) | ADRA2CTSHRHPGDHTTALDH1A1 | |
| SCHEMBL5353769 | 0.83 | ALDH1A1 (0.51) | TSHRALDH1A1POLBGLAMLYCD | |
| SCHEMBL8439016 | 0.83 | ALDH1A1 (0.47) | TSHRHPGDALDH1A1POLBGLA | |
| SCHEMBL28294373 | 0.81 | ALDH1A1 (0.46) | TSHRALDH1A1POLBGLAMLYCD | |
| SCHEMBL29873818 | 0.81 | ALDH1A1 (0.46) | TSHRHTTALDH1A1POLBGLA | |
| SCHEMBL10527468 | 0.81 | ATM (0.56) | HTTALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL698882 | 0.80 | ADRA2C (0.64) | ADRA2CTSHRHPGDHTTALDH1A1 | |
| SCHEMBL6901524 | 0.80 | MLYCD (0.50) | TSHRALDH1A1GLAMLYCDSMN1; SMN2 | |
| SCHEMBL7119736 | 0.79 | MLYCD (0.40) | TSHRALDH1A1POLBGLAMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1114815-B1 | Process to prepare taxol | UPJOHN CO (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1114815-A2 | Process to prepare taxol | PHARMACIA & UPJOHN COMPANY (US) | 2001-07-11 | — | — | EP | claimed |
| EP-1114815-B1 | Process to prepare taxol | UPJOHN CO (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1383771-A1 | 9-DEAZAGUANINE DERIVATIVES AS INHIBITORS OF GSK-3 | Vertex Pharmaceuticals Incorporated (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1352900-A1 | Process to prepare taxol | PHARMACIA & UPJOHN COMPANY (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352899-A1 | Process to prepare taxol | PHARMACIA & UPJOHN COMPANY (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030096813-A1 | Compositions useful as inhibitors of GSK-3 | CAO JINGRONG (US) | 2003-05-22 | — | — | US | disclosed |
| WO-2002085909-A1 | 9-DEAZAGUANINE DERIVATIVES AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-10-31 | — | — | WO | disclosed |
| EP-0912504-B1 | Oxazolidine ester | UPJOHN CO (US) | 2002-09-11 | — | — | EP | disclosed |
| US-6307064-B1 | PHENYLISOSERINE ESTER OF SILYLATED BACCATIN III | PHARMACIA & UPJOHN COMPANY | 2001-10-23 | — | — | US | disclosed |
| EP-1114815-A2 | Process to prepare taxol | PHARMACIA & UPJOHN COMPANY (US) | 2001-07-11 | — | — | EP | disclosed |
| US-6177573-B1 | Process to prepare taxol | PHARMACIA & UPJOHN COMPANY | 2001-01-23 | — | — | US | disclosed |
| US-6057452-A | Process to prepare taxol | PHARMACIA & UPJOHN COMPANY | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096813-A1 | Compositions useful as inhibitors of GSK-3 | GSK3B, GSK3A, GSKIP | ADRA2C 1884/4885TSHR 3679/4885HPGD 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.